January 12, 2026
Breakthrough T1D is pleased that the European Commission has approved Tezeild (Tzield in the U.S.) to delay the onset of stage 3 type 1 diabetes (T1D) in individuals with stage 2 T1D who are eight years of age and older. The approval represents an important step forward for the global T1D community.
Tezeild is the first disease-modifying therapy that addresses the root cause of T1D, not the symptoms. It has been shown to delay the onset of stage 3 T1D by an average of three years and has been approved for use in the UK, China, Canada, Israel, the Kingdom of Saudi Arabia, the United Arab Emirates, and Kuwait.
Read more in Sanofi’s press release.
